The authors reply

類似資料

• Sacubitril/valsartan in peritoneal dialysis—lessons from a pharmacokinetic study
  著者:: Judge, PK, 等
  出版事項: (2023)
• Allocated but not treated: the silent 16% – Authors' reply
  著者:: Horby, P, 等
  出版事項: (2022)
• Authors' reply
  著者:: Herrington, W, 等
  出版事項: (2018)
• Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
  著者:: Judge, PK, 等
  出版事項: (2023)
• The prevention and management of chronic kidney disease among patients with metabolic syndrome
  著者:: Zhu, D, 等
  出版事項: (2025)